Ranked #1 Children's Hospital by U.S. News & World Report
MyPatients provides referring primary care providers with secure access to their patients’ information.
Boston Children's has launched the world's 1st program dedicated to offering hand transplants to children who qualify.
Innovation insider is a semi-monthly e-newsletter analyzes innovations at Boston Children’s, other academic medical centers and from industry.
Read the latest blog by a Boston Children's doctor, clinician or staff member.
Support the hospital with a donation that helps kids get the care they need.
Diffuse intrinsic pontine gliomas (DIPG) are highly aggressive and difficult to treat brain tumors found at the base of the brain. They are glial tumors, meaning they arise from the brain's glial tissue—tissue made up of cells that help support and protect the brain's neurons. These tumors are found in an area of the brainstem (the lowest, stem-like part of the brain) called the pons, which controls many of the body's most vital functions such as breathing, blood pressure, and heart rate.
Approximately 300 children are diagnosed with diffuse intrinsic pontine gliomas (DIPG) each year, usually between the ages of 5 and 9. Although the prognosis for diffuse intrinsic pontine gliomas remains very poor, new research led by Dana-Farber/Boston Children's may provide the key to improved treatment options.
Children and adolescents with diffuse intrinsic pontine gliomas (DIPG) are treated at Dana-Farber/Boston Children's Cancer and Blood Disorders Center through our Glioma Program, one of the world’s largest pediatric glioma treatment programs. Our brain tumor specialists have extensive expertise in treating all types of gliomas, including DIPGs.
Find in-depth information on diffuse intrinsic pontine gliomas (DIPG) on the Dana-Farber/Boston Children’s website, including answers to:
The future of pediatrics will be forged by thinking differently, breaking paradigms and joining together in a shared vision of tackling the toughest challenges before us.”